BIRC5 and neoplasm: In another study, immunization with a plasmid encoding survivin, a tumor-associated antigen, along with the administration of systemic recombinant T. cruzi Calreticulin (rTcCRT), had a synergistic effect on inhibiting tumor growth and inducing humoral anti-rTcCRT immunity in a B16-F10 melanoma murine model [276].